INmune Bio Inc. (INMB) News
Track canonical SquawkNews coverage tagged to INMB, INmune Bio Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
INmune Bio Receives $4.6M R&D Rebates
INmune Bio gets $4.6M R&D rebates
EQUITY | Jul 31, 2026, 11:00 AM UTC
L
INMB - INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th - Click For Rele
INMB - INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
EARNINGS | Jul 31, 2026, 11:00 AM UTC
M
INMB Establishes Scientific Advisory Board
INMB forms advisory board for CORDStrom platform
EQUITY | Jul 30, 2026, 11:00 AM UTC
L
INMB Inmune bio’s xpro1595 prevents brain-injury-induced Alzheimer's pathology, memory loss, and pain in new peer-reviewed preclinical study
INMB Inmune bio’s xpro1595 prevents brain-injury-induced Alzheimer's pathology, memory loss, and pain in new peer-reviewed preclinical study Inmune Bio - xpro1595 selectively neutralizes soluble tnf - Cordstrom to file m
EQUITY | Jul 15, 2026, 11:02 AM UTC
L
INmune Bio Submits Its CORDStrom Platform Patent Application Into The U.S. National Phase Before USPTO
Submission advances a key element of the Company’s global intellectual property strategy for its next-generation mesenchymal stromal cell (MSC) platform. Highlights Advanced to U.S. National Phase: The Company has offici
EQUITY | Jul 01, 2026, 11:07 AM UTC
H
INMB: UK Approves PIP
The UK Medicines & Healthcare Products Regulatory Agency approves the Pediatric Investigation Plan for INmune Bio's Ebstrocel for Recessive Dystrophic Epidermolysis Bullosa
EQUITY | Jun 25, 2026, 11:13 AM UTC
M
INMB Gets MHRA Approval
INmune Bio Inc. achieves MHRA approval of PIP for CORDStrom
EQUITY | Jun 25, 2026, 11:00 AM UTC
M
INMB Receives MHRA Alignment
INmune Bio receives MHRA written alignment supporting planned 2026 UK conditional marketing authorization application for CORDStrom in RDEB
EQUITY | Jun 23, 2026, 12:02 PM UTC